Literature DB >> 18759337

Predictive value of nigrostriatal dysfunction in isolated tremor: a clinical and SPECT study.

Roberto Ceravolo1, Angelo Antonini, Duccio Volterrani, Carlo Rossi, Lorenzo Kiferle, Daniela Frosini, Claudio Lucetti, Ioannis U Isaias, Riccardo Benti, Luigi Murri, Ubaldo Bonuccelli.   

Abstract

The overlap among tremor disorders is wide and complex because essential tremor patients may present resting tremor coexisting with postural tremor, while postural may coexist with resting tremor in Parkinson's disease. We investigated dopamine transporter binding in 61 subjects presenting with isolated atypical tremors defined as unilateral either postural, resting, or mixed (i.e. resting and postural) tremor, without rigidity or bradykinesia, by means of 123I-FPCIT SPECT imaging at baseline. Patients were followed-up clinically for 28.4 +/- 7.2 months. Twenty-five patients with baseline normal SPECT continued to present only tremor at follow-up. Among 36 patients with abnormal SPECT, 23 (64%) developed PD, while the remaining 13 continued to present only tremor at follow-up. The value of 123I-FPCIT SPECT in predicting the evolution to PD was very high in a way independent from the first clinical presentation of tremor (Rest tremor, P = 0.015; Mixed tremor, P = 0.015; Postural tremor, P = 0.039; chi-square test). Our data suggest that the clinical presentation of isolated tremors is insufficient to allow a precise early-stage diagnosis, whereas the detection of presynaptic nigrostriatal dopaminergic dysfunction could lead to diagnosis of atypical tremor disorders at a very early stage. We suggest this disorder to be labeled as "isolated tremor with dopaminergic presynaptic dysfunction". (c) 2008 Movement Disorder Society.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18759337     DOI: 10.1002/mds.22259

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  9 in total

Review 1.  Neuroimaging biomarkers for Parkinson disease: facts and fantasy.

Authors:  Joel S Perlmutter; Scott A Norris
Journal:  Ann Neurol       Date:  2014-11-07       Impact factor: 10.422

2.  Essential tremor and Parkinson's disease: lack of a link.

Authors:  Charles H Adler; Holly A Shill; Thomas G Beach
Journal:  Mov Disord       Date:  2011-01-31       Impact factor: 10.338

3.  Expert testimony at the Food and Drug Administration: who wants the truth?

Authors:  Joel S Perlmutter
Journal:  Narrat Inq Bioeth       Date:  2011

4.  Ultrasonographic (TCS) and clinical findings in overlapping phenotype of essential tremor and Parkinson's disease (ET-PD).

Authors:  Kristina Laučkaitė; Daiva Rastenytė; Danguolė Šurkienė; Birutė Vaidelytė; Gabrielė Dambrauskaitė; Andrius Sakalauskas; Antanas Vaitkus; Rymantė Gleiznienė
Journal:  BMC Neurol       Date:  2014-03-22       Impact factor: 2.474

Review 5.  Molecular Imaging of the Dopamine Transporter.

Authors:  Giovanni Palermo; Roberto Ceravolo
Journal:  Cells       Date:  2019-08-10       Impact factor: 6.600

Review 6.  The Molecular Neuroimaging of Tremor.

Authors:  Jacopo Pasquini; Roberto Ceravolo
Journal:  Curr Neurol Neurosci Rep       Date:  2021-11-24       Impact factor: 5.081

Review 7.  Dopamine Transporter Imaging, Current Status of a Potential Biomarker: A Comprehensive Review.

Authors:  Giovanni Palermo; Sara Giannoni; Gabriele Bellini; Gabriele Siciliano; Roberto Ceravolo
Journal:  Int J Mol Sci       Date:  2021-10-18       Impact factor: 5.923

Review 8.  Essential tremor plus rest tremor: current concepts and controversies.

Authors:  Roberto Erro; Cristiano Sorrentino; Maria Russo; Paolo Barone
Journal:  J Neural Transm (Vienna)       Date:  2022-06-07       Impact factor: 3.850

9.  Cohort study of prevalence and phenomenology of tremor in dementia with Lewy bodies.

Authors:  Marco Onofrj; Sara Varanese; Laura Bonanni; John-Paul Taylor; Angelo Antonini; Enza Maria Valente; Simona Petrucci; Fabrizio Stocchi; Astrid Thomas; Bernardo Perfetti
Journal:  J Neurol       Date:  2013-02-12       Impact factor: 4.849

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.